Evidence Snapshot

Macrophage colony-stimulating factor 1 receptor

CHEMBL1844 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:08Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1844

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Macrophage colony-stimulating factor 1 receptor as ChEMBL target CHEMBL1844, mapped to UniProt P07333. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Macrophage colony-stimulating factor 1 receptor

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL1844

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P07333

Macrophage colony-stimulating factor 1 receptor

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Macrophage colony-stimulating factor 1 receptor matters

As of 2026-09-13

Macrophage colony-stimulating factor 1 receptor is reviewed as Macrophage colony-stimulating factor 1 receptor (UniProt P07333); Macrophage colony-stimulating factor 1 receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 11 linked drugs keep this evidence frame grounded.; the current evidence base includes 37 approved drugs, 4824 compounds, and 877 assays, with lead potency reaching pChEMBL 9.7.

Protein context

Macrophage colony-stimulating factor 1 receptor

Macrophage colony-stimulating factor 1 receptor Sequence length is 972 aa.

Review this target as Macrophage colony-stimulating factor 1 receptor, mapped to UniProt P07333. Sequence length is 972 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P07333 Protein

Disease context

neoplasm

Macrophage colony-stimulating factor 1 receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ARRY-382, AXATILIMAB, EMACTUZUMAB.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include ARRY-382, AXATILIMAB, EMACTUZUMAB, IMC-CS4. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 11 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 37 approved drugs, 4824 compounds, and 877 assays for this target. The dominant activity type is IC50. CHEMBL5415149 is the current potency anchor at pChEMBL 9.7.

Use CHEMBL5415149 as the tractability anchor when discussing potency (pChEMBL 9.7).

Activity source · ChEMBL 36 via Core Engine

37 approved pChEMBL 9.7

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Macrophage colony-stimulating factor 1 receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P07333, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4824

Total Compounds

877

Total Assays

Approved Drugs

IC50: 3946.0, KI: 1002.0, EC50: 2.0, KD: 214.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5415149	9.7	IC50	—
No preferred name CHEMBL438533	9.5	IC50	—
No preferred name CHEMBL489684	9.5	IC50	—
No preferred name CHEMBL1171604	9.5	IC50	—
No preferred name CHEMBL5404686	9.5	IC50	—

Approved Drugs

Structure	Compound	First Approval
	QUIZARTINIB CHEMBL576982	2023
	PACRITINIB CHEMBL2035187	2022
	FILGOTINIB CHEMBL3301607	2020
	ENTRECTINIB CHEMBL1983268	2019
	FEDRATINIB CHEMBL1287853	2019
	PEXIDARTINIB CHEMBL3813873	2019
	NERATINIB CHEMBL180022	2017
	BRIGATINIB CHEMBL3545311	2017
	MIDOSTAURIN CHEMBL608533	2017
	NINTEDANIB CHEMBL502835	2014
	PONATINIB CHEMBL1171837	2012
	BOSUTINIB CHEMBL288441	2012
	AXITINIB CHEMBL1289926	2012
	CRIZOTINIB CHEMBL601719	2011
	PAZOPANIB CHEMBL477772	2009
	NILOTINIB CHEMBL255863	2007
	SUNITINIB CHEMBL535	2006
	DASATINIB CHEMBL5416410	2006
	SUNITINIB MALATE CHEMBL1567	2006
	DASATINIB ANHYDROUS CHEMBL1421	2006
	SORAFENIB CHEMBL1336	2005
	IMATINIB CHEMBL941	2001

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:08Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1844